Particularly in PaCa, oncogenic KRAS contributes to Exo uptake by yet undefined mechanisms such that long-term persisting Exo manipulated to target oncogenic KRAS is currently the most efficient therapeutics (163). This evidence concerns the gene KRAS and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.